Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Everolimus
Cat. No.:
OB0225LY-0371
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
Everolimus is a rapamycin derivative that inhibits cell proliferation and neovascularization.
Synonym:
RAD001; SDZ-RAD; 159351-69-6; 40-O-(2-Hydroxyethyl)-rapamycin; 40-O-(2-Hydroxyethyl)rapamycin; Afinitor; Certican; Everolimus; RapamyciN, 42-O-(2-hydroxyethyl)-
CAS No.:
159351-69-6
Compound CID:
6442177
Formula:
C53H83NO14
Formula Weight:
958.22
Specification
Relative Density:
1.18 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Everolimus can be used to study cell cycle regulation and tumor biology or play an important role in the immune response.
Library Information
Targets:
PI3K/Akt/mTOR pathway
Receptors:
FKBP; mTOR1
Pathways:
Autophagy; Apoptosis; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-5
Plate Location:
g6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
50 mg/mL; 52.18 mM
Ethanol Max Solubility:
50 mg/mL
Solubility:
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (5.22 mM), insoluble in water.
ALogP:
6.164
HBA_Count:
11
HBD_Count:
2
Rotatable Bond:
9
